The present technology relates generally to systems for delivering prosthetic heart valve devices. In particular, several embodiments of the present technology are related to delivery systems with telescoping capsules for percutaneously delivering prosthetic heart valve devices and associated methods.
Heart valves can be affected by several conditions. For example, mitral valves can be affected by mitral valve regurgitation, mitral valve prolapse and mitral valve stenosis. Mitral valve regurgitation is abnormal leaking of blood from the left ventricle into the left atrium caused by a disorder of the heart in which the leaflets of the mitral valve fail to coapt into apposition at peak contraction pressures. The mitral valve leaflets may not coapt sufficiently because heart diseases often cause dilation of the heart muscle, which in turn enlarges the native mitral valve annulus to the extent that the leaflets do not coapt during systole. Abnormal backflow can also occur when the papillary muscles are functionally compromised due to ischemia or other conditions. More specifically, as the left ventricle contracts during systole, the affected papillary muscles do not contract sufficiently to effect proper closure of the leaflets.
Mitral valve prolapse is a condition when the mitral leaflets bulge abnormally up in to the left atrium. This can cause irregular behavior of the mitral valve and lead to mitral valve regurgitation. The leaflets may prolapse and fail to coapt because the tendons connecting the papillary muscles to the inferior side of the mitral valve leaflets (chordae tendineae) may tear or stretch. Mitral valve stenosis is a narrowing of the mitral valve orifice that impedes filling of the left ventricle in diastole.
Mitral valve regurgitation is often treated using diuretics and/or vasodilators to reduce the amount of blood flowing back into the left atrium. Surgical approaches (open and intravascular) for either the repair or replacement of the valve have also been used to treat mitral valve regurgitation. For example, typical repair techniques involve cinching or resecting portions of the dilated annulus. Cinching, for example, includes implanting annular or peri-annular rings that are generally secured to the annulus or surrounding tissue. Other repair procedures suture or clip the valve leaflets into partial apposition with one another.
Alternatively, more invasive procedures replace the entire valve itself by implanting mechanical valves or biological tissue into the heart in place of the native mitral valve. These invasive procedures conventionally require large open thoracotomies and are thus very painful, have significant morbidity, and require long recovery periods. Moreover, with many repair and replacement procedures, the durability of the devices or improper sizing of annuloplasty rings or replacement valves may cause additional problems for the patient. Repair procedures also require a highly skilled cardiac surgeon because poorly or inaccurately placed sutures may affect the success of procedures.
Less invasive approaches to aortic valve replacement have been implemented in recent years. Examples of pre-assembled, percutaneous prosthetic valves include, e.g., the CoreValve Revalving® System from Medtronic/Corevalve Inc. (Irvine, Calif., USA) and the EdwardsSapien® Valve from Edwards Lifesciences (Irvine, Calif., USA). Both valve systems include an expandable frame and a tri-leaflet bioprosthetic valve attached to the expandable frame. The aortic valve is substantially symmetric, circular, and has a muscular annulus. The expandable frames in aortic applications have a symmetric, circular shape at the aortic valve annulus to match the native anatomy, but also because tri-leaflet prosthetic valves require circular symmetry for proper coaptation of the prosthetic leaflets. Thus, aortic valve anatomy lends itself to an expandable frame housing a replacement valve since the aortic valve anatomy is substantially uniform, symmetric, and fairly muscular. Other heart valve anatomies, however, are not uniform, symmetric or sufficiently muscular, and thus transvascular aortic valve replacement devises may not be well suited for other types of heart valves.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the illustrated component is necessarily transparent. The headings provided herein are for convenience only.
The present technology is generally directed to delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods. Specific details of several embodiments of the present technology are described herein with reference to
With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference relative positions of portions of a prosthetic valve device and/or an associated delivery device with reference to an operator and/or a location in the vasculature or heart. For example, in referring to a delivery catheter suitable to deliver and position various prosthetic valve devices described herein, “proximal” can refer to a position closer to the operator of the device or an incision into the vasculature, and “distal” can refer to a position that is more distant from the operator of the device or further from the incision along the vasculature (e.g., the end of the catheter). With respect to a prosthetic heart valve device, the terms “proximal” and “distal” can refer to the location of portions of the device with respect to the direction of blood flow. For example, proximal can refer to an upstream position or a location where blood flows into the device (e.g., inflow region), and distal can refer to a downstream position or a location where blood flows out of the device (e.g., outflow region).
Overview
Several embodiments of the present technology are directed to delivery systems and mitral valve replacement devices that address the unique challenges of percutaneously replacing native mitral valves and are well-suited to be recaptured in a percutaneous delivery device after being partially deployed for repositioning or removing the device. Compared to replacing aortic valves, percutaneous mitral valve replacement faces unique anatomical obstacles that render percutaneous mitral valve replacement significantly more challenging than aortic valve replacement. First, unlike relatively symmetric and uniform aortic valves, the mitral valve annulus has a non-circular D-shape or kidney-like shape, with a non-planar, saddle-like geometry often lacking symmetry. The complex and highly variable anatomy of mitral valves makes it difficult to design a mitral valve prosthesis that conforms well to the native mitral annulus of specific patients. As a result, the prosthesis may not fit well with the native leaflets and/or annulus, which can leave gaps that allows backflow of blood to occur. For example, placement of a cylindrical valve prosthesis in a native mitral valve may leave gaps in commissural regions of the native valve through which perivalvular leaks may occur.
Current prosthetic valves developed for percutaneous aortic valve replacement are unsuitable for use in mitral valves. First, many of these devices require a direct, structural connection between the stent-like structure that contacts the annulus and/or leaflets and the prosthetic valve. In several devices, the stent posts which support the prosthetic valve also contact the annulus or other surrounding tissue. These types of devices directly transfer the forces exerted by the tissue and blood as the heart contracts to the valve support and the prosthetic leaflets, which in turn distorts the valve support from its desired cylindrical shape. This is a concern because most cardiac replacement devices use tri-leaflet valves, which require a substantially symmetric, cylindrical support around the prosthetic valve for proper opening and closing of the three leaflets over years of life. As a result, when these devices are subject to movement and forces from the annulus and other surrounding tissues, the prostheses may be compressed and/or distorted causing the prosthetic leaflets to malfunction. Moreover, a diseased mitral annulus is much larger than any available prosthetic aortic valve. As the size of the valve increases, the forces on the valve leaflets increase dramatically, so simply increasing the size of an aortic prosthesis to the size of a dilated mitral valve annulus would require dramatically thicker, taller leaflets, and might not be feasible.
In addition to its irregular, complex shape, which changes size over the course of each heartbeat, the mitral valve annulus lacks a significant amount of radial support from surrounding tissue. Compared to aortic valves, which are completely surrounded by fibro-elastic tissue that provides sufficient support for anchoring a prosthetic valve, mitral valves are bound by muscular tissue on the outer wall only. The inner wall of the mitral valve anatomy is bound by a thin vessel wall separating the mitral valve annulus from the inferior portion of the aortic outflow tract. As a result, significant radial forces on the mitral annulus, such as those imparted by an expanding stent prostheses, could lead to collapse of the inferior portion of the aortic tract. Moreover, larger prostheses exert more force and expand to larger dimensions, which exacerbates this problem for mitral valve replacement applications.
The chordae tendineae of the left ventricle may also present an obstacle in deploying a mitral valve prosthesis. Unlike aortic valves, mitral valves have a maze of cordage under the leaflets in the left ventricle that restrict the movement and position of a deployment catheter and the replacement device during implantation. As a result, deploying, positioning and anchoring a valve replacement device on the ventricular side of the native mitral valve annulus is complicated.
Embodiments of the present technology provide systems, methods and apparatus to treat heart valves of the body, such as the mitral valve, that address the challenges associated with the anatomy of the mitral valve and provide for repositioning and removal of a partially deployed device. The apparatus and methods enable a percutaneous approach using a catheter delivered intravascularly through a vein or artery into the heart, or through a cannula inserted through the heart wall. For example, the apparatus and methods are particularly well-suited for trans-septal and trans-apical approaches, but can also be trans-atrial and direct aortic delivery of a prosthetic replacement valve to a target location in the heart. Additionally, the embodiments of the devices and methods as described herein can be combined with many known surgeries and procedures, such as known methods of accessing the valves of the heart (e.g., the mitral valve or triscuspid valve) with antegrade or retrograde approaches, and combinations thereof.
The systems and methods described herein facilitate delivery of a prosthetic heart valve device using trans-septal delivery approaches to a native mitral valve and allow resheathing of the prosthetic heart valve device after partial deployment of the device to reposition and/or remove the device. The delivery systems can include a telescoping delivery capsule that has a first housing and a second housing slidably disposed within at least a portion of the first housing. During deployment, the first housing moves in a distal direction over the second housing to release a portion of the prosthetic heart valve device, and then the first and second housings move together in a distal direction to fully deploy the prosthetic heart valve device. This telescoping arrangement of the first and second housings requires the delivery capsule to traverse a short overall longitudinal distance relative to the device positioned therein for device deployment and, therefore, facilitates deployment within the constraints of native anatomy surrounding the mitral valve. In addition, when in the initial delivery state, the disclosed telescoping delivery capsules can have a short overall length relative to the length of the prosthetic heart valve device stored therein, which facilitates delivery along tightly curved paths necessary to access the native mitral valve via trans-septal delivery. The disclosed delivery systems can also be used to delivery other medical devices to other target sites with native anatomy that benefits from a compact delivery capsule and reduced longitudinal translation for deployment.
Access to the Mitral Valve
To better understand the structure and operation of valve replacement devices in accordance with the present technology, it is helpful to first understand approaches for implanting the devices. The mitral valve or other type of atrioventricular valve can be accessed through the patient's vasculature in a percutaneous manner. By percutaneous it is meant that a location of the vasculature remote from the heart is accessed through the skin, typically using a surgical cut down procedure or a minimally invasive procedure, such as using needle access through, for example, the Seldinger technique. The ability to percutaneously access the remote vasculature is well known and described in the patent and medical literature. Depending on the point of vascular access, access to the mitral valve may be antegrade and may rely on entry into the left atrium by crossing the inter-atrial septum (e.g., a trans-septal approach). Alternatively, access to the mitral valve can be retrograde where the left ventricle is entered through the aortic valve. Access to the mitral valve may also be achieved using a cannula via a trans-apical approach. Depending on the approach, the interventional tools and supporting catheter(s) may be advanced to the heart intravascularly and positioned adjacent the target cardiac valve in a variety of manners, as described herein.
In an alternative antegrade approach (not shown), surgical access may be obtained through an intercostal incision, preferably without removing ribs, and a small puncture or incision may be made in the left atrial wall. A guide catheter passes through this puncture or incision directly into the left atrium, sealed by a purse string-suture.
The antegrade or trans-septal approach to the mitral valve, as described above, can be advantageous in many respects. For example, antegrade approaches will usually enable more precise and effective centering and stabilization of the guide catheter and/or prosthetic valve device. The antegrade approach may also reduce the risk of damaging the chordae tendinae or other subvalvular structures with a catheter or other interventional tool. Additionally, the antegrade approach may decrease risks associated with crossing the aortic valve as in retrograde approaches. This can be particularly relevant to patients with prosthetic aortic valves, which cannot be crossed at all or without substantial risk of damage.
Selected Embodiments of Delivery Systems for Prosthetic Heart Valve Devices
The handle assembly 110 can include a control assembly 126 to initiate deployment of the device 102 from the telescoping delivery capsule 108 at the target site. The control assembly 126 may include rotational elements, buttons, levers, and/or other actuators that allow a clinician to control rotational position of the delivery capsule 108, as well as the deployment and/or resheathing mechanisms of the delivery system 100. For example, the illustrated control assembly 126 includes a first actuator 130 operably coupled to the first housing 112 via the catheter body 106 to control distal and proximal movement of the first housing 112 and a second actuator 132 operably coupled to the second housing 114 via the catheter body 106 to control proximal and distal movement of the second housing 114. In other embodiments, a single actuator, more than two actuators, and/or other features can be used to initiate movement of the first and second housings 112 and 114. The handle assembly 110 can also include a steering mechanism 128 that provides steering capability (e.g., 360 degree rotation of the delivery capsule 108, 180 degree rotation of the delivery capsule 108, 3-axis steering, 2-axis steering, etc.) for delivering the delivery capsule 108 to a target site (e.g., to a native mitral valve). The steering mechanism 128 can be used to steer the catheter 104 through the anatomy by bending the distal portion 106a of the catheter body 106 about a transverse axis. In other embodiments, the handle assembly 110 may include additional and/or different features that facilitate delivering the device 102 to the target site. In certain embodiments, the catheter 104 can be configured to travel over a guidewire 124, which can be used to guide the delivery capsule 108 into the native mitral valve.
As shown in
In certain embodiments, the fluid assembly 116 may comprise a controller 122 that controls the movement of fluid to and from the catheter 104. The controller 122 can include, without limitation, one or more computers, central processing units, processing devices, microprocessors, digital signal processors (DSPs), and/or application-specific integrated circuits (ASICs). To store information, for example, the controller 122 can include one or more storage elements, such as volatile memory, non-volatile memory, read-only memory (ROM), and/or random access memory (RAM). The stored information can include pumping programs, patient information, and/or other executable programs. The controller 122 can further include a manual input device (e.g., a keyboard, a touch screen, etc.) and/or an automated input device (e.g., a computer, a data storage device, servers, network, etc.). In still other embodiments, the controller 122 may include different features and/or have a different arrangement for controlling the flow of fluid into and out of the fluid source 118.
The delivery capsule 108 includes the first housing 112 and the second housing 114, which can each contain at least a portion of the device 102 in the containment configuration. The second housing 114 can have an opening 134 at its distal end portion through which the guidewire 124 can be threaded to allow for guidewire delivery to the target site. As shown in
As discussed above, the first housing 112 slides or otherwise moves relative to the second housing 114 in a telescoping manner to release a portion of the device 102 from the delivery capsule 108 and, optionally, resheathe the device 102 after partial deployment. In certain embodiments, the first and second housings 112 and 114 are hydraulically actuated via the handle assembly 110 and/or the fluid assembly 116. In hydraulically-actuated embodiments, the delivery capsule 108 includes a first fluid chamber configured to receive a flowable material from the fluid assembly 116 to move the first housing 112 relative to the second housing 114. The delivery capsule 108 can further include a second fluid chamber configured to receive a flowable material from the fluid assembly 116 to move the first and second housing 112 and 114 as a unit. During the first deployment stage, a clinician can use the first actuator 130 and/or other suitable control means to deliver fluid (e.g., water or saline) from the fluid source 118 to the first fluid chamber to move the first housing 112 in a distal direction over the second housing 114 to release a first portion of the device 102 from the delivery capsule 108. During the second deployment stage, the clinician can use the second actuator 132 and/or other suitable control means to deliver fluid from the fluid source 118 to the second fluid chamber such that the first and second housings 112 and 114 move together in the distal direction to release a second portion of the device 102 from the delivery capsule 108 until the device 102 is partially or fully unsheathed from the delivery capsule 108. The first actuator 130, the second actuator 132, and/or other features can also be used to remove fluid from the first and second fluid chambers to allow for resheathing of the device 102 or close the delivery capsule 108. In other embodiments, the first housing 112 and/or the second housing 114 can be moved distally and proximally for unsheathing and resheathing using mechanical means, such as wire tethers.
The ability of the first housing 112 to move relative to the second housing 114 in a telescoping manner to deploy the device 102 results in a delivery capsule 108 that is relatively compact in length (e.g., a length of 40 mm or less) and that requires relatively short overall longitudinal translation (e.g., 50 mm or less, 40 mm or less, etc.) to deploy the device 102. For example, the telescoping delivery capsule 108 inherently requires less longitudinal translation for deployment than if the delivery capsule 108 were defined by a single housing that moves distally or proximally to deploy the device 102, or two separate housings that move in opposite directions to deploy the device 102. This shorter longitudinal translation in solely the distal direction facilitates trans-septal delivery of the device 102 to a native mitral valve of a human patient. For a typical patient with functional mitral valve regurgitation (“FMR”), the distance across the left atrium is estimated to be about 50 mm and the length of the left ventricle is estimated to be about 70 mm. During trans-septal delivery of the device 102, the delivery capsule 108 can extend through the opening in the septal wall between the right and left atria and be positioned in or proximate to the mitral valve annulus by bending the distal portion 106a of the catheter body 106 from the left atrium into the mitral valve. The compact size of the delivery capsule 108 facilitates positioning the delivery capsule 108 into the left atrium and making the turn into the native mitral valve without being limited by the anatomical sizing of the right atrium. During device deployment, the telescoping delivery capsule 108 does not require any portion of the delivery capsule 108 to extend in a proximal direction into the left atrium of the heart, and the telescoping arrangement of the first and second housings 112 and 114 results in a short overall longitudinal translation (relative to the axial length of the device 102) of the housings 112, 114 into the left ventricle of the heart, much less than typical length of the left ventricle. Thus, the telescoping delivery capsule 108 avoids the typical constraints associated with trans-septal delivery and the associated anatomy proximate to the target site in the mitral valve.
The delivery capsule 108 further includes a plurality of sealing members (identified individually as first through third sealing members 140a-c, respectively; referred to collectively as “sealing members 140”), such as sealing sleeves and/or O-rings, that can fluidically seal portions of the delivery capsule to define a first fluid chamber 142, a second fluid chamber 144, and/or portions thereof. The sealing members 140 can be sleeves, O-rings, O-rings positioned within sleeves, and/or other sealing features that are fixedly attached to the first housing 112, the second housing 114, and/or other portions of the delivery capsule 108 via bonding, laser welding, and/or other mechanisms for securing the sealing members 140 in position on portions of the delivery capsule 108. In certain embodiments, for example, the first and second housings 112 and 114 can include sleeves or flanges formed in or on the surfaces of the housings 112, 114 (e.g., using 3D printing) and configured to receive O-rings and/or other sealing features. As shown in
The second fluid chamber 144 is positioned within the second housing 114 and can be defined at a proximal end by the third sealing member 140c. As shown in
The platform 150 is fixed relative to the body 106 and/or another shaft extending therethrough, and can be configured to support a distal end portion of a prosthetic heart valve device (e.g., the device 102 of
The end feature 152 at the distal portion 154 of the second housing 114 can be a nose cone or other element that provides stability to the distal end of the delivery capsule 108 and/or defines an atraumatic tip to facilitate intraluminal delivery of the capsule 108. The end feature 152 can be integrally formed at the distal end portion 154 of the second housing 114, a separate component fixedly attached thereto, or defined by the distal end of the second housing 114. As shown in
As further shown in
The delivery system 100 further includes fluid lines (identified individually as a first fluid line 158a and a second fluid line 158b; referred to collectively as “fluid lines 158”) in fluid communication with the first and second fluid chambers 142 and 144 via fluid ports (identified individually as a first fluid port 160a and a second fluid port 160b; referred to collectively as “fluid ports 160”). As shown in
At the distal portion 106a of the catheter body 106, the first fluid line 158a extends in a distal direction from the main catheter body 106, through the distal end of the second housing 114 (e.g., through the channel 155 of the end feature 152 and through the opening 134), outside the second housing 114, and into the first fluid port 160a in fluid communication with the first fluid chamber 142. In the embodiment illustrated in
As further shown in
In various embodiments, the delivery capsule 108 can also be configured to partially or fully resheathe the prosthetic heart valve device after partial deployment from the delivery capsule 108.
The telescoping delivery capsule 108 and the delivery system 100 described above with respect to
In other embodiments, the telescoping delivery capsule 108 can operate in the opposite manner with respect to the distal portion 106a of the catheter body 106 such that the telescoping housings 112, 114 are configured to retract in a proximal direction to deploy the device 102 from the delivery capsule 108 and move in a distal direction to resheathe the device 102. Such an embodiment would be suitable to deliver the device 102 to the mitral valve from the left ventricle using a trans-apical approach (e.g., via an opening formed in the apical portion of the left ventricle). For example, the hydraulic actuation mechanism can move the first and second housings 112 and 114 in a proximal direction in a telescoping manner toward the distal portion 106a of the catheter body 106 to unsheathe the device 102. Once the device 102 is fully deployed within the mitral valve, the retracted delivery capsule 108 (with the first housing 112 at least partially overlapping the second housing 114) can be pulled in a proximal direction through the left ventricle and the apical aperture to remove the delivery system 100.
During device deployment, the first fluid chamber 142 is pressurized with fluid, thereby causing the first sealing member 140a and the first housing 112 to slide distally until the proximal sealing member 140d comes into contact with the internal second sealing member 140b (e.g., about 20 mm). This unsheathes at least a portion of the device 102 from the delivery capsule 108. Further unsheathing can be performed by pressurizing the second fluid chamber 144 with fluid to hydraulically move the telescoped first and second housings 112 and 114 together in the distal direction to partially or completely unsheathe the device 102. In other embodiments, the telescoped first and second housings 112 and 114 are moved together in the distal direction using mechanical means. To retract the first housing 112, the first fluid chamber 142 is evacuated of fluid and the third fluid chamber 143 is pressurized with fluid via the third fluid line 158c. This causes the proximal sealing member 140d and the first housing 112 to slide proximally, e.g., until the first sealing member 140a stops against the internal second sealing member 140b. Accordingly, the supplemental third fluid chamber 143 can be used to facilitate resheathing of the device 102 and/or retraction of the delivery capsule 108 back to its delivery state. In some embodiments, the delivery capsule 108 can include additional fluid chambers that further facilitate device deployment and recapture, and/or the fluid chambers can be defined by different portions of the delivery capsule 108, while still being configured to hydraulically drive the first and second housings 112 and 114 distally and/or proximally relative to each other.
As illustrated in
As further shown in
The biasing devices 262 can also limit or substantially prevent distal movement of the housings 112, 114 attributable to the forces produced by an expanding prosthetic heart valve device (e.g., the device 102 of
In the embodiment illustrated in
In operation, fluid is delivered to the first fluid chamber 342 via the first fluid line 358a, which causes the first housing 312 to move in a distal direction over the second housing 314 to unsheathe a portion of a prosthetic heart valve device (e.g., the device 102 of
Rather than the hydraulically-actuated first and second housings described with reference to
The tether elements 664 extend from the first housing 612 in a distal direction over a distal end portion 654 of the second housing 614 (e.g., a nose cone), into a distal opening 634 of the second housing 614, and in a proximal direction through the catheter body 606. At a proximal portion of the delivery system 600, proximal end portions of the tether elements 664 can be attached to actuators of a handle assembly (e.g., the handle assembly 110 of
The remainder of the prosthetic heart valve device can be unsheathed from the delivery capsule 608 in a subsequent deployment step by moving the second housing 614 (together with the first housing 612) in a distal direction. For example, the second housing 614 can be driven in the distal direction using mechanical means (e.g., rods or pistons) to push the second housing 614 distally, or the second housing 614 can move via hydraulic means by moving fluid to one or more fluid chambers (e.g., similar to the fluid chambers described above with reference to
In various embodiments, the delivery capsule 608 can further be configured to allow for resheathing a partially deployed device and/or otherwise moving the delivery capsule 608 back toward its initial delivery state. A clinician pushes or otherwise moves the tether elements 664 in the distal direction (e.g., via an actuator on a proximally-positioned handle assembly), thereby moving the first housing 612 in a proximal direction. To accommodate such distal movement of the tether elements 664, each tether element 664 can be routed through an individual tube or channel that extends through the catheter body 606 and allows the clinician to both pull and push the tether elements 664, while inhibiting the tether elements 664 from buckling along the length of the catheter body 606 during proximal movement. In other embodiments, the tether elements 664 and/or portions thereof can be made from semi-rigid and/or rigid materials that avoid buckling when the tether elements 664 are not placed in tension.
The first and second tether elements 764a and 764b are configured to drive the first housing 712 in the distal direction to at least partially unsheathe a proximal heart valve device and/or other device stored within the delivery capsule 708. Similar to the tether elements 664 of
The third and fourth tether elements 764c and 764d are used to mechanically drive the first housing 712 in the proximal direction to at least partially resheathe the device and/or close the delivery capsule 708 for removal from the patient. Distal end portions of the third and fourth tether elements 764c and 764d are coupled to a distal end portion of the first housing 712 at two corresponding attachment features 770, such as adhesives, interlocking components, hooks, eyelets, and/or other suitable fasteners for joining one end portion of the tether elements 764 to the first housing 712. As shown in
In operation, the clinician can at least partially unsheathe the device by proximally retracting the first and second tether elements 764a and 764b to move the first housing 712 in the distal direction toward the unsheathing state. The clinician can further unsheathe the device by moving the second housing 714 in the distal direction. If resheathing is desired to adjust position or remove the device from the patient, the clinician can proximally retract the third and fourth tether elements 764c and 764d to move the first housing 712 back over the device in the proximal direction to resheathe a portion of the device within the first housing 712. After full deployment of the device at the target site, proximal retraction of the third and fourth tether elements 764c and 764d can again be used to move the first housing 712 proximally such that the delivery capsule 708 is placed back into the delivery state for removal from the patient. Accordingly, the delivery system 700 uses proximal retraction of the tether elements 764 to mechanically drive the first housing 712 in both the distal and proximal directions. Similar to the telescoping delivery capsules described above, the delivery capsule 708 of
Selected Embodiments of Prosthetic Heart Valve Devices
The telescoping delivery systems 100, 200a, 200b, 300, 600 and 700 described above with reference to
In the embodiment shown in
Referring still to
The device 1100 can further include a first sealing member 1162 on the valve support 1110 and a second sealing member 1164 on the anchoring member 1120. The first and second sealing members 1162, 1164 can be made from a flexible material, such as Dacron® or another type of polymeric material. The first sealing member 1162 can cover the interior and/or exterior surfaces of the valve support 1110. In the embodiment illustrated in
The device 1100 can further include an extension member 1170. The extension member 1170 can be an extension of the second sealing member 1164, or it can be a separate component attached to the second sealing member 1164 and/or the first portion 1132 of the fixation structure 1130. The extension member 1170 can be a flexible member that, in a deployed state (
Referring to
In several embodiments, the fixation structure 1130 can be a generally cylindrical fixation ring having an outwardly facing engagement surface. For example, in the embodiment shown in
The embodiment of the device 1100 shown in
Referring to
In one embodiment, the arms 1124 have a first length from the base 1122 to the smooth bend 1140, and the structural elements 1137 of the fixation structure 1130 at each side of a cell 1138 (
In the embodiment illustrated in
The extended connectors 1210 further include an attachment element 1214 configured to releasably engage a delivery device. The attachment element 1214 can be a T-bar or other element that prevents the device 1200 from being released from the capsule 1700 (
Referring to
Each of the first hexagonal cells 1312 includes a pair of first longitudinal supports 1314, a downstream apex 1315, and an upstream apex 1316. Each of the second hexagonal cells 1322 can include a pair of second longitudinal supports 1324, a downstream apex 1325, and an upstream apex 1326. The first and second rows 1310 and 1312 of the first and second hexagonal cells 1312 and 1322 are directly adjacent to each other. In the illustrated embodiment, the first longitudinal supports 1314 extend directly from the downstream apexes 1325 of the second hexagonal cells 1322, and the second longitudinal supports 1324 extend directly from the upstream apexes 1316 of the first hexagonal cells 1312. As a result, the first hexagonal cells 1312 are offset from the second hexagonal cells 1322 around the circumference of the valve support 1300 by half of the cell width.
In the embodiment illustrated in
The first longitudinal supports 1314 can include a plurality of holes 1336 through which sutures can pass to attach a prosthetic valve assembly and/or a sealing member. In the embodiment illustrated in
Referring to
The valve support 1300 illustrated in
Several aspects of the present technology are set forth in the following examples.
1. A system for delivering a prosthetic heart valve device into a heart of a patient, the system comprising:
2. The system of example 1 wherein the delivery capsule further comprises:
3. The system of example 2, further comprising a platform extending from the elongated catheter body into the second housing, wherein the platform includes a distal end portion slidably sealed against an inner wall of the second housing and defines a proximal end of the second fluid chamber.
4. The system of example 2 or 3 wherein the first sealing member is a first sleeve extending inwardly from the first housing, and the second sealing member is a second sleeve extending outwardly from the second housing.
5. The system of any one of examples 2-4 wherein, after the second deployment stage, the first fluid chamber is configured to be evacuated of fluid while the second fluid chamber remains pressurized with fluid such that the first housing moves in a proximal direction.
6. The system of any one of examples 2-5, further comprising:
7. The system of example 6 wherein the first fluid lumen passes through the second housing and into a port in the first housing, wherein the port is in fluid communication with the first fluid chamber.
8. The system of example 6 wherein second housing has an inner channel in a wall of the second housing, and wherein the inner channel is in fluid communication with the first fluid chamber and defines a portion of the first fluid lumen.
9. The system of any one of examples 1-8 wherein the delivery capsule has an overall length of at most 50 mm.
10. The system of any one of examples 1-9 wherein the delivery capsule has an overall length of at most 40 mm.
11. The system of any one of examples 1-10 wherein the first housing and the second housing each have a length of at most 30 mm.
12. The system of any one of examples 1-11, further comprising:
13. The system of example 1 wherein the second housing includes an arched feature on an outer surface of the second housing and positioned between the first and second housings, wherein the system further comprises:
14. A system for delivering a prosthetic heart valve device into a heart of a patient, the system comprising:
15. The system of example 14 wherein the delivery capsule further comprises:
16. The system of example 14 or 15, further comprising a platform extending from the elongated catheter body into the second housing, wherein the platform includes a distal end portion slidably sealed against an inner wall of the second housing, and wherein the distal end portion of the platform defines a proximal end of the second fluid chamber.
17. The system of any one of examples 14-16 wherein, during a resheathing phase, the first fluid chamber is configured to be evacuated of fluid while the second fluid chamber remains pressurized with fluid to allow the first housing to slide in a proximal direction over the second housing.
18. The system of any one of examples 14-17, further comprising:
19. The system of example 18 wherein the first fluid lumen passes into the second housing, outside the first and second housings, and into a port in the first housing, wherein the port is in fluid communication with the first fluid chamber.
20. The system of example 18 wherein the first lumen is defined in part by an inner channel of the second housing.
21. The system of any one of examples 14-20 wherein the first and second housings each have a length of 20-30 mm.
22. The system of any one of examples 14-21, further comprising:
23. A method for delivering a prosthetic heart valve device to a native mitral valve of a heart of a human patient, the method comprising:
24. The method of example 23, further comprising evacuating fluid from the first fluid chamber while the second fluid chamber remains pressurized with fluid such that the first housing slides in a proximal direction over the second housing.
25. The method of example 23 or 24 wherein positioning the delivery capsule within the heart comprises delivering the delivery capsule across an atrial septum of the heart to a left atrium.
26. A method for delivering a prosthetic heart valve device to a native mitral valve of a heart of a human patient, the method comprising:
The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
Number | Name | Date | Kind |
---|---|---|---|
3526219 | Balamuth | Sep 1970 | A |
3565062 | Kuris | Feb 1971 | A |
3589363 | Banko et al. | Jun 1971 | A |
3667474 | Lapkin et al. | Jun 1972 | A |
3823717 | Pohlman et al. | Jul 1974 | A |
3861391 | Antonevich et al. | Jan 1975 | A |
3896811 | Storz | Jul 1975 | A |
4042979 | Angell | Aug 1977 | A |
4188952 | Loschilov et al. | Feb 1980 | A |
4282882 | Langham | Aug 1981 | A |
4431006 | Trimmer et al. | Feb 1984 | A |
4445509 | Auth | May 1984 | A |
4484579 | Meno et al. | Nov 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4587958 | Noguchi et al. | May 1986 | A |
4589419 | Laughlin et al. | May 1986 | A |
4602911 | Ahmadi et al. | Jul 1986 | A |
4646736 | Auth | Mar 1987 | A |
4649922 | Wiktor | Mar 1987 | A |
4692139 | Stiles | Sep 1987 | A |
4747821 | Kensey et al. | May 1988 | A |
4750902 | Wuchinich et al. | Jun 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787388 | Hofmann | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4808153 | Parisi | Feb 1989 | A |
4819751 | Shimada et al. | Apr 1989 | A |
4841977 | Griffith et al. | Jun 1989 | A |
4870953 | DonMicheal et al. | Oct 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4898575 | Fischell et al. | Feb 1990 | A |
4909252 | Goldberger | Mar 1990 | A |
4919133 | Chiang | Apr 1990 | A |
4920954 | Alliger et al. | May 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4960411 | Buchbinder | Oct 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4990134 | Auth | Feb 1991 | A |
5058570 | Idemoto et al. | Oct 1991 | A |
5069664 | Guess et al. | Dec 1991 | A |
5076276 | Sakurai et al. | Dec 1991 | A |
5106302 | Farzin-Nia et al. | Apr 1992 | A |
5248296 | Alliger | Sep 1993 | A |
5267954 | Nita | Dec 1993 | A |
5269291 | Carter | Dec 1993 | A |
5295958 | Shturman | Mar 1994 | A |
5304115 | Pflueger et al. | Apr 1994 | A |
5314407 | Auth et al. | May 1994 | A |
5318014 | Carter | Jun 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5352199 | Tower | Oct 1994 | A |
5356418 | Shturman | Oct 1994 | A |
5397293 | Alliger et al. | Mar 1995 | A |
5411025 | Webster, Jr. | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5489297 | Duran | Feb 1996 | A |
5584879 | Reimold et al. | Dec 1996 | A |
5609151 | Mulier et al. | Mar 1997 | A |
5626603 | Venturelli et al. | May 1997 | A |
5656036 | Palmaz | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5681336 | Clement et al. | Oct 1997 | A |
5695507 | Auth et al. | Dec 1997 | A |
5725494 | Brisken | Mar 1998 | A |
5782931 | Yang et al. | Jul 1998 | A |
5817101 | Fiedler | Oct 1998 | A |
5827229 | Auth et al. | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5868781 | Killion | Feb 1999 | A |
5873811 | Wang et al. | Feb 1999 | A |
5904679 | Clayman | May 1999 | A |
5910129 | Koblish et al. | Jun 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5972004 | Williamson, IV et al. | Oct 1999 | A |
5989208 | Nita | Nov 1999 | A |
5989280 | Euteneuer | Nov 1999 | A |
6047700 | Eggers et al. | Apr 2000 | A |
6056759 | Fiedler | May 2000 | A |
6085754 | Alferness et al. | Jul 2000 | A |
6113608 | Monroe et al. | Sep 2000 | A |
RE36939 | Tachibana et al. | Oct 2000 | E |
6129734 | Shturman et al. | Oct 2000 | A |
6132444 | Shturman et al. | Oct 2000 | A |
6159139 | Chiu | Dec 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6217595 | Shturman et al. | Apr 2001 | B1 |
6254635 | Schroeder et al. | Jul 2001 | B1 |
6295712 | Shturman et al. | Oct 2001 | B1 |
6306414 | Koike | Oct 2001 | B1 |
6321109 | Ben-Haim et al. | Nov 2001 | B2 |
6402679 | Mortier et al. | Jun 2002 | B1 |
6423032 | Parodi | Jul 2002 | B2 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6454737 | Nita et al. | Sep 2002 | B1 |
6454757 | Nita et al. | Sep 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6494890 | Shturman et al. | Dec 2002 | B1 |
6494891 | Cornish et al. | Dec 2002 | B1 |
6505080 | Sutton | Jan 2003 | B1 |
6514261 | Randall et al. | Feb 2003 | B1 |
6530952 | Vesely | Mar 2003 | B2 |
6540782 | Snyders | Apr 2003 | B1 |
6562067 | Mathis | May 2003 | B2 |
6565588 | Clement et al. | May 2003 | B1 |
6569196 | Vesely | May 2003 | B1 |
6579308 | Jansen et al. | Jun 2003 | B1 |
6582460 | Cryer | Jun 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6595912 | Lau et al. | Jul 2003 | B2 |
6605109 | Fiedler | Aug 2003 | B2 |
6616689 | Ainsworth et al. | Sep 2003 | B1 |
6623452 | Chien et al. | Sep 2003 | B2 |
6638288 | Shturman et al. | Oct 2003 | B1 |
6648854 | Patterson et al. | Nov 2003 | B1 |
6689086 | Nita et al. | Feb 2004 | B1 |
6702748 | Nita et al. | Mar 2004 | B1 |
6730121 | Ortiz et al. | May 2004 | B2 |
6746463 | Schwartz | Jun 2004 | B1 |
6811801 | Nguyen et al. | Nov 2004 | B2 |
6818001 | Wulfman et al. | Nov 2004 | B2 |
6843797 | Nash et al. | Jan 2005 | B2 |
6852118 | Shturman et al. | Feb 2005 | B2 |
6855123 | Nita | Feb 2005 | B2 |
6869439 | White et al. | Mar 2005 | B2 |
6951571 | Srivastava | Oct 2005 | B1 |
6986775 | Morales et al. | Jan 2006 | B2 |
7018404 | Holmberg et al. | Mar 2006 | B2 |
7052487 | Cohn et al. | May 2006 | B2 |
7077861 | Spence | Jul 2006 | B2 |
7125420 | Rourke et al. | Oct 2006 | B2 |
7163552 | Diaz | Jan 2007 | B2 |
7186264 | Liddicoat et al. | Mar 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7296577 | Lashinski et al. | Nov 2007 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7473275 | Marquez | Jan 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7588582 | Starksen et al. | Sep 2009 | B2 |
7621948 | Herrmann et al. | Nov 2009 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753922 | Starksen | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7803168 | Gifford et al. | Sep 2010 | B2 |
7857845 | Stacchino et al. | Dec 2010 | B2 |
7896915 | Guyenot et al. | Mar 2011 | B2 |
7942928 | Webler et al. | May 2011 | B2 |
7985238 | Balgobin et al. | Jul 2011 | B2 |
8002826 | Seguin | Aug 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8114154 | Righini | Feb 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8398704 | Straubinger et al. | Mar 2013 | B2 |
8403981 | Forster et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8496671 | Hausen | Jul 2013 | B1 |
8512252 | Ludomirsky et al. | Aug 2013 | B2 |
8518107 | Tsukashima et al. | Aug 2013 | B2 |
8523883 | Saadat | Sep 2013 | B2 |
8532352 | Ionasec et al. | Sep 2013 | B2 |
8540767 | Zhang | Sep 2013 | B2 |
8545551 | Loulmet | Oct 2013 | B2 |
8551161 | Dolan | Oct 2013 | B2 |
8579788 | Orejola | Nov 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8597347 | Maurer et al. | Dec 2013 | B2 |
8597348 | Rowe et al. | Dec 2013 | B2 |
8608796 | Matheny | Dec 2013 | B2 |
8608797 | Gross et al. | Dec 2013 | B2 |
8623077 | Cohn | Jan 2014 | B2 |
8628566 | Eberhardt et al. | Jan 2014 | B2 |
8632585 | Seguin et al. | Jan 2014 | B2 |
8632586 | Spenser et al. | Jan 2014 | B2 |
8634935 | Gaudiani | Jan 2014 | B2 |
8647254 | Callas et al. | Feb 2014 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8652204 | Quill et al. | Feb 2014 | B2 |
8657872 | Seguin | Feb 2014 | B2 |
8672998 | Lichtenstein et al. | Mar 2014 | B2 |
8673001 | Cartledge et al. | Mar 2014 | B2 |
8679176 | Matheny | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8688234 | Zhu et al. | Apr 2014 | B2 |
8690858 | Machold et al. | Apr 2014 | B2 |
8709074 | Solem et al. | Apr 2014 | B2 |
8712133 | Guhring et al. | Apr 2014 | B2 |
8715160 | Raman et al. | May 2014 | B2 |
8721665 | Oz et al. | May 2014 | B2 |
8721718 | Kassab | May 2014 | B2 |
8740918 | Seguin | Jun 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8758431 | Orlov et al. | Jun 2014 | B2 |
8758432 | Solem | Jun 2014 | B2 |
8771292 | Allen et al. | Jul 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8771346 | Tuval et al. | Jul 2014 | B2 |
8777991 | Zarbatany et al. | Jul 2014 | B2 |
8778016 | Janovsky et al. | Jul 2014 | B2 |
8781580 | Hedberg et al. | Jul 2014 | B2 |
8784482 | Randert et al. | Jul 2014 | B2 |
8792699 | Guetter et al. | Jul 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8801779 | Seguin et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8808366 | Braido et al. | Aug 2014 | B2 |
8812431 | Voigt et al. | Aug 2014 | B2 |
8828043 | Chambers | Sep 2014 | B2 |
8845717 | Khairkhahan et al. | Sep 2014 | B2 |
8845723 | Spence et al. | Sep 2014 | B2 |
8852213 | Gammie et al. | Oct 2014 | B2 |
8852272 | Gross et al. | Oct 2014 | B2 |
8858622 | Machold et al. | Oct 2014 | B2 |
8859724 | Meier et al. | Oct 2014 | B2 |
8864822 | Spence et al. | Oct 2014 | B2 |
8870936 | Rowe | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8870949 | Rowe | Oct 2014 | B2 |
8894702 | Quadri et al. | Nov 2014 | B2 |
8900214 | Nance et al. | Dec 2014 | B2 |
8900295 | Migliazza et al. | Dec 2014 | B2 |
8926694 | Costello | Jan 2015 | B2 |
8932348 | Solem et al. | Jan 2015 | B2 |
8951285 | Sugimoto et al. | Feb 2015 | B2 |
8961597 | Subramanian et al. | Feb 2015 | B2 |
8968393 | Rothstein | Mar 2015 | B2 |
8968395 | Hauser et al. | Mar 2015 | B2 |
8974445 | Warnking et al. | Mar 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8979923 | Spence et al. | Mar 2015 | B2 |
8986370 | Annest | Mar 2015 | B2 |
8986376 | Solem | Mar 2015 | B2 |
8992604 | Gross et al. | Mar 2015 | B2 |
9011522 | Annest | Apr 2015 | B2 |
9011523 | Seguin | Apr 2015 | B2 |
9017399 | Gross et al. | Apr 2015 | B2 |
9023098 | Kuehn | May 2015 | B2 |
9023100 | Quadri et al. | May 2015 | B2 |
9023101 | Krahbichler | May 2015 | B2 |
9050188 | Schweich, Jr. et al. | Jun 2015 | B2 |
9066800 | Clague et al. | Jun 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9095433 | Lutter et al. | Aug 2015 | B2 |
9119713 | Board et al. | Sep 2015 | B2 |
9132009 | Hacohen et al. | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9138313 | McGuckin, Jr. et al. | Sep 2015 | B2 |
9180005 | Lashinski et al. | Nov 2015 | B1 |
9192466 | Kovalsky et al. | Nov 2015 | B2 |
9192471 | Bolling | Nov 2015 | B2 |
9226825 | Starksen et al. | Jan 2016 | B2 |
9232942 | Seguin et al. | Jan 2016 | B2 |
9232998 | Wilson et al. | Jan 2016 | B2 |
9232999 | Maurer et al. | Jan 2016 | B2 |
9241790 | Lane et al. | Jan 2016 | B2 |
9248014 | Lane et al. | Feb 2016 | B2 |
9254192 | Lutter et al. | Feb 2016 | B2 |
9259317 | Wilson et al. | Feb 2016 | B2 |
9271833 | Kim et al. | Mar 2016 | B2 |
9289291 | Gorman, III et al. | Mar 2016 | B2 |
9289297 | Wilson et al. | Mar 2016 | B2 |
9289927 | Weber et al. | Mar 2016 | B2 |
9295547 | Costello et al. | Mar 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
9308087 | Lane et al. | Apr 2016 | B2 |
9326850 | Venkatasubramanian | May 2016 | B2 |
9326852 | Spenser | May 2016 | B2 |
9333073 | Quadri et al. | May 2016 | B2 |
9333074 | Quadri et al. | May 2016 | B2 |
9339378 | Quadri et al. | May 2016 | B2 |
9339379 | Quadri et al. | May 2016 | B2 |
9339380 | Quadri et al. | May 2016 | B2 |
9339382 | Tabor et al. | May 2016 | B2 |
9358108 | Bortlein et al. | Jun 2016 | B2 |
9387075 | Bortlein et al. | Jul 2016 | B2 |
9387078 | Gross et al. | Jul 2016 | B2 |
9393111 | Ma et al. | Jul 2016 | B2 |
9425916 | Nakao et al. | Aug 2016 | B2 |
9579198 | Deem et al. | Feb 2017 | B2 |
9629719 | Rothstein et al. | Apr 2017 | B2 |
9675454 | Vidlund et al. | Jun 2017 | B2 |
9681951 | Ratz et al. | Jun 2017 | B2 |
9687342 | Figulla et al. | Jun 2017 | B2 |
9687343 | Bortlein et al. | Jun 2017 | B2 |
9693859 | Braido et al. | Jul 2017 | B2 |
9693862 | Campbell et al. | Jul 2017 | B2 |
9694121 | Alexander et al. | Jul 2017 | B2 |
9700409 | Braido et al. | Jul 2017 | B2 |
9700411 | Klima et al. | Jul 2017 | B2 |
9730791 | Ratz et al. | Aug 2017 | B2 |
9730794 | Carpentier et al. | Aug 2017 | B2 |
9750605 | Ganesan et al. | Sep 2017 | B2 |
9750606 | Ganesan et al. | Sep 2017 | B2 |
9750607 | Ganesan et al. | Sep 2017 | B2 |
9763657 | Hacohen et al. | Sep 2017 | B2 |
9763658 | Eigler et al. | Sep 2017 | B2 |
9763782 | Solem et al. | Sep 2017 | B2 |
9770328 | Macoviak | Sep 2017 | B2 |
9788931 | Giordano et al. | Oct 2017 | B2 |
9801717 | Edquist et al. | Oct 2017 | B2 |
9827092 | Vidlund et al. | Nov 2017 | B2 |
9827101 | Solem et al. | Nov 2017 | B2 |
9833313 | Board et al. | Dec 2017 | B2 |
9833315 | Vidlund et al. | Dec 2017 | B2 |
9839511 | Ma et al. | Dec 2017 | B2 |
9844435 | Eidenschink | Dec 2017 | B2 |
9848880 | Coleman et al. | Dec 2017 | B2 |
9848983 | Lashinski et al. | Dec 2017 | B2 |
9861477 | Backus et al. | Jan 2018 | B2 |
9861480 | Zakai et al. | Jan 2018 | B2 |
9968453 | Vola et al. | May 2018 | B2 |
10258468 | Deem et al. | Apr 2019 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020007219 | Merrill et al. | Jan 2002 | A1 |
20020013571 | Goldfarb et al. | Jan 2002 | A1 |
20020072792 | Burgermeister et al. | Jun 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020082637 | Lumauig | Jun 2002 | A1 |
20020099439 | Schwartz et al. | Jul 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020173841 | Ortiz et al. | Nov 2002 | A1 |
20030120340 | Liska et al. | Jun 2003 | A1 |
20030139689 | Shturman et al. | Jul 2003 | A1 |
20040006358 | Wulfman et al. | Jan 2004 | A1 |
20040039412 | Isshiki et al. | Feb 2004 | A1 |
20040044350 | Martin et al. | Mar 2004 | A1 |
20040057955 | O'Brien et al. | Mar 2004 | A1 |
20040082910 | Constantz et al. | Apr 2004 | A1 |
20040092858 | Wilson et al. | May 2004 | A1 |
20040092962 | Thornton et al. | May 2004 | A1 |
20040092989 | Wilson et al. | May 2004 | A1 |
20040106989 | Wilson et al. | Jun 2004 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040122510 | Sarac | Jun 2004 | A1 |
20040127979 | Wilson et al. | Jul 2004 | A1 |
20040127982 | Machold et al. | Jul 2004 | A1 |
20040186558 | Pavcnik et al. | Sep 2004 | A1 |
20040199191 | Schwartz | Oct 2004 | A1 |
20040230117 | Tosaya et al. | Nov 2004 | A1 |
20040230212 | Wulfman | Nov 2004 | A1 |
20040230213 | Wulfman et al. | Nov 2004 | A1 |
20040243162 | Wulfman et al. | Dec 2004 | A1 |
20050007219 | Ma et al. | Jan 2005 | A1 |
20050075662 | Pedersen et al. | Apr 2005 | A1 |
20050075720 | Nguyen et al. | Apr 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050107661 | Lau et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137698 | Salahieh et al. | Jun 2005 | A1 |
20050137700 | Spence et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050267523 | Devellian et al. | Dec 2005 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060106456 | Machold et al. | May 2006 | A9 |
20060142833 | Von Oepen et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060167543 | Bailey et al. | Jul 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20070056346 | Spenser et al. | Mar 2007 | A1 |
20070061010 | Hauser et al. | Mar 2007 | A1 |
20070073391 | Bourang et al. | Mar 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070173932 | Cali et al. | Jul 2007 | A1 |
20070203561 | Forster et al. | Aug 2007 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080103586 | Styrc et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080234728 | Starksen et al. | Sep 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080243246 | Ryan et al. | Oct 2008 | A1 |
20090024137 | Chuter et al. | Jan 2009 | A1 |
20090054969 | Salahieh et al. | Feb 2009 | A1 |
20090076586 | Hauser et al. | Mar 2009 | A1 |
20090076598 | Salahieh et al. | Mar 2009 | A1 |
20090093670 | Annest et al. | Apr 2009 | A1 |
20090157174 | Yoganathan et al. | Jun 2009 | A1 |
20090164006 | Seguin et al. | Jun 2009 | A1 |
20090198315 | Boudjemline | Aug 2009 | A1 |
20090216312 | Straubinger et al. | Aug 2009 | A1 |
20090240320 | Tuval et al. | Sep 2009 | A1 |
20090259292 | Bonhoeffer | Oct 2009 | A1 |
20090259306 | Rowe | Oct 2009 | A1 |
20090264997 | Salahieh et al. | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281609 | Benichou et al. | Nov 2009 | A1 |
20090281618 | Hill et al. | Nov 2009 | A1 |
20090292350 | Eberhardt et al. | Nov 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20090319037 | Rowe et al. | Dec 2009 | A1 |
20090319038 | Gurskis et al. | Dec 2009 | A1 |
20100016958 | St. Goar et al. | Jan 2010 | A1 |
20100023117 | Yoganathan et al. | Jan 2010 | A1 |
20100030330 | Bobo et al. | Feb 2010 | A1 |
20100035703 | Ishikawa et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100121436 | Tuval et al. | May 2010 | A1 |
20100160931 | Karpiel et al. | Jun 2010 | A1 |
20100185275 | Richter et al. | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100249915 | Zhang | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100298929 | Thornton et al. | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20100324554 | Gifford et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110015722 | Hauser et al. | Jan 2011 | A1 |
20110022166 | Dahlgren et al. | Jan 2011 | A1 |
20110029071 | Zlotnick et al. | Feb 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110040374 | Goetz et al. | Feb 2011 | A1 |
20110040375 | Letac et al. | Feb 2011 | A1 |
20110066231 | Cartledge et al. | Mar 2011 | A1 |
20110066233 | Thornton et al. | Mar 2011 | A1 |
20110112632 | Chau et al. | May 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110137409 | Yang et al. | Jun 2011 | A1 |
20110137410 | Hacohen | Jun 2011 | A1 |
20110153008 | Marchand et al. | Jun 2011 | A1 |
20110172784 | Richter et al. | Jul 2011 | A1 |
20110184512 | Webler et al. | Jul 2011 | A1 |
20110201874 | Birk et al. | Aug 2011 | A1 |
20110208293 | Tabor | Aug 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110319988 | Schankereli et al. | Dec 2011 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120035703 | Lutter et al. | Feb 2012 | A1 |
20120035713 | Lutter et al. | Feb 2012 | A1 |
20120053680 | Bolling et al. | Mar 2012 | A1 |
20120053682 | Kovalsky et al. | Mar 2012 | A1 |
20120078347 | Braido et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120165930 | Gifford, III et al. | Jun 2012 | A1 |
20120179239 | Quadri | Jul 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120203336 | Annest | Aug 2012 | A1 |
20120283824 | Lutter et al. | Nov 2012 | A1 |
20130035628 | Garrison et al. | Feb 2013 | A1 |
20130138090 | Fargahi | May 2013 | A1 |
20130172978 | Vidlund et al. | Jul 2013 | A1 |
20130190860 | Sundt, III | Jul 2013 | A1 |
20130190861 | Chau et al. | Jul 2013 | A1 |
20130197354 | Maschke et al. | Aug 2013 | A1 |
20130197630 | Azarnoush | Aug 2013 | A1 |
20130204356 | Dwork et al. | Aug 2013 | A1 |
20130204358 | Matheny | Aug 2013 | A1 |
20130226289 | Shaolian et al. | Aug 2013 | A1 |
20130226290 | Yellin et al. | Aug 2013 | A1 |
20130231735 | Deem | Sep 2013 | A1 |
20130238089 | Lichtenstein et al. | Sep 2013 | A1 |
20130244927 | Lal et al. | Sep 2013 | A1 |
20130253641 | Lattouf | Sep 2013 | A1 |
20130253642 | Brecker | Sep 2013 | A1 |
20130253643 | Rolando et al. | Sep 2013 | A1 |
20130259337 | Guhring et al. | Oct 2013 | A1 |
20130261737 | Costello | Oct 2013 | A1 |
20130261738 | Clague et al. | Oct 2013 | A1 |
20130261739 | Kuehn | Oct 2013 | A1 |
20130261741 | Accola | Oct 2013 | A1 |
20130268066 | Rowe | Oct 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130282059 | Ketai et al. | Oct 2013 | A1 |
20130282060 | Tuval | Oct 2013 | A1 |
20130282110 | Schweich, Jr. et al. | Oct 2013 | A1 |
20130289642 | Hedberg et al. | Oct 2013 | A1 |
20130289717 | Solem | Oct 2013 | A1 |
20130289718 | Tsukashima et al. | Oct 2013 | A1 |
20130296851 | Boronyak et al. | Nov 2013 | A1 |
20130296999 | Burriesci et al. | Nov 2013 | A1 |
20130304180 | Green et al. | Nov 2013 | A1 |
20130304181 | Green | Nov 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20130304198 | Solem | Nov 2013 | A1 |
20130304200 | McLean et al. | Nov 2013 | A1 |
20130309292 | Andersen | Nov 2013 | A1 |
20130310436 | Lowes et al. | Nov 2013 | A1 |
20130310925 | Eliasen et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130317603 | McLean et al. | Nov 2013 | A1 |
20130325110 | Khalil et al. | Dec 2013 | A1 |
20130325114 | McLean et al. | Dec 2013 | A1 |
20130331864 | Jelich et al. | Dec 2013 | A1 |
20130338684 | Hausen | Dec 2013 | A1 |
20130338763 | Rowe et al. | Dec 2013 | A1 |
20130345797 | Dahlgren et al. | Dec 2013 | A1 |
20130345803 | Bergheim, III | Dec 2013 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140018906 | Rafiee | Jan 2014 | A1 |
20140018913 | Cartledge et al. | Jan 2014 | A1 |
20140023261 | Watanabe et al. | Jan 2014 | A1 |
20140025164 | Montorfano et al. | Jan 2014 | A1 |
20140031928 | Murphy et al. | Jan 2014 | A1 |
20140046219 | Sauter et al. | Feb 2014 | A1 |
20140046436 | Kheradvar | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140052240 | Zhang | Feb 2014 | A1 |
20140056906 | Yue et al. | Feb 2014 | A1 |
20140066895 | Kipperman | Mar 2014 | A1 |
20140067048 | Chau et al. | Mar 2014 | A1 |
20140067052 | Chau et al. | Mar 2014 | A1 |
20140067054 | Chau et al. | Mar 2014 | A1 |
20140088071 | Nakai et al. | Mar 2014 | A1 |
20140088680 | Costello et al. | Mar 2014 | A1 |
20140088693 | Seguin et al. | Mar 2014 | A1 |
20140088695 | Figulla et al. | Mar 2014 | A1 |
20140094906 | Spence et al. | Apr 2014 | A1 |
20140107775 | Hjelle et al. | Apr 2014 | A1 |
20140114404 | Gammie et al. | Apr 2014 | A1 |
20140114407 | Rajamannan | Apr 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140128965 | Rafiee | May 2014 | A1 |
20140135913 | Lichtenstein et al. | May 2014 | A1 |
20140163652 | Witzel et al. | Jun 2014 | A1 |
20140163668 | Rafiee | Jun 2014 | A1 |
20140172076 | Jonsson et al. | Jun 2014 | A1 |
20140172084 | Callas et al. | Jun 2014 | A1 |
20140172085 | Quadri et al. | Jun 2014 | A1 |
20140172086 | Quadri et al. | Jun 2014 | A1 |
20140179993 | Alexander et al. | Jun 2014 | A1 |
20140180401 | Quill et al. | Jun 2014 | A1 |
20140188108 | Goodine et al. | Jul 2014 | A1 |
20140188215 | Hlavka et al. | Jul 2014 | A1 |
20140194920 | Krahbichler | Jul 2014 | A1 |
20140194969 | Headley | Jul 2014 | A1 |
20140194976 | Starksen et al. | Jul 2014 | A1 |
20140200397 | Raman et al. | Jul 2014 | A1 |
20140200649 | Essinger | Jul 2014 | A1 |
20140200657 | Maurer et al. | Jul 2014 | A1 |
20140200662 | Eftel et al. | Jul 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140219524 | Takeguchi et al. | Aug 2014 | A1 |
20140222040 | Park et al. | Aug 2014 | A1 |
20140222135 | Forster et al. | Aug 2014 | A1 |
20140222138 | Machold et al. | Aug 2014 | A1 |
20140225946 | Quinn et al. | Aug 2014 | A1 |
20140228942 | Krahbichler | Aug 2014 | A1 |
20140228946 | Chau et al. | Aug 2014 | A1 |
20140242056 | Karandikar et al. | Aug 2014 | A1 |
20140242086 | Lal et al. | Aug 2014 | A1 |
20140243560 | Lorenz et al. | Aug 2014 | A1 |
20140243860 | Morris et al. | Aug 2014 | A1 |
20140243954 | Shannon | Aug 2014 | A1 |
20140243964 | Venkatasubramanian | Aug 2014 | A1 |
20140249621 | Eidenschink | Sep 2014 | A1 |
20140257101 | Gaudiani | Sep 2014 | A1 |
20140257466 | Board et al. | Sep 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140257473 | Rajamannan | Sep 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140275757 | Goodwin et al. | Sep 2014 | A1 |
20140276395 | Wilson et al. | Sep 2014 | A1 |
20140276609 | Magee et al. | Sep 2014 | A1 |
20140276782 | Paskar | Sep 2014 | A1 |
20140276971 | Kovach | Sep 2014 | A1 |
20140277119 | Akpinar | Sep 2014 | A1 |
20140277390 | Ratz et al. | Sep 2014 | A1 |
20140277404 | Wilson et al. | Sep 2014 | A1 |
20140277405 | Wilson et al. | Sep 2014 | A1 |
20140277406 | Arcidi | Sep 2014 | A1 |
20140277407 | Dale et al. | Sep 2014 | A1 |
20140277408 | Folan | Sep 2014 | A1 |
20140277409 | Bortlein et al. | Sep 2014 | A1 |
20140277410 | Bortlein et al. | Sep 2014 | A1 |
20140277411 | Bortlein et al. | Sep 2014 | A1 |
20140277412 | Bortlein et al. | Sep 2014 | A1 |
20140277420 | Migliazza et al. | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140288480 | Zimmerman et al. | Sep 2014 | A1 |
20140296878 | Oz et al. | Oct 2014 | A1 |
20140296969 | Tegels et al. | Oct 2014 | A1 |
20140296970 | Ekvall et al. | Oct 2014 | A1 |
20140296971 | Tegels et al. | Oct 2014 | A1 |
20140296975 | Tegels et al. | Oct 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140303721 | Fung et al. | Oct 2014 | A1 |
20140309727 | Lamelas et al. | Oct 2014 | A1 |
20140309730 | Alon et al. | Oct 2014 | A1 |
20140309731 | Quadri et al. | Oct 2014 | A1 |
20140309732 | Solem | Oct 2014 | A1 |
20140316516 | Vidlund et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140358222 | Gorman, III et al. | Dec 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140364944 | Lutter et al. | Dec 2014 | A1 |
20140371843 | Wilson et al. | Dec 2014 | A1 |
20140371844 | Dale et al. | Dec 2014 | A1 |
20140371846 | Wilson et al. | Dec 2014 | A1 |
20140379074 | Spence et al. | Dec 2014 | A1 |
20140379076 | Vidlund et al. | Dec 2014 | A1 |
20150004165 | Yue et al. | Jan 2015 | A1 |
20150005874 | Vidlund et al. | Jan 2015 | A1 |
20150005875 | Tuval et al. | Jan 2015 | A1 |
20150012069 | Puskas | Jan 2015 | A1 |
20150018353 | Kim et al. | Jan 2015 | A1 |
20150018940 | Quill et al. | Jan 2015 | A1 |
20150025311 | Kadan et al. | Jan 2015 | A1 |
20150025623 | Granada et al. | Jan 2015 | A1 |
20150032127 | Gammie et al. | Jan 2015 | A1 |
20150045878 | Rowe | Feb 2015 | A1 |
20150057738 | Hepke et al. | Feb 2015 | A1 |
20150066138 | Alexander et al. | Mar 2015 | A1 |
20150066140 | Quadri et al. | Mar 2015 | A1 |
20150094802 | Buchbinder et al. | Apr 2015 | A1 |
20150094803 | Navia | Apr 2015 | A1 |
20150100116 | Mohl et al. | Apr 2015 | A1 |
20150112427 | Schweich, Jr. et al. | Apr 2015 | A1 |
20150112429 | Khairkhahan et al. | Apr 2015 | A1 |
20150112433 | Schweich, Jr. et al. | Apr 2015 | A1 |
20150119978 | Tegels et al. | Apr 2015 | A1 |
20150119981 | Khairkhahan et al. | Apr 2015 | A1 |
20150119982 | Quill et al. | Apr 2015 | A1 |
20150127091 | Cecere et al. | May 2015 | A1 |
20150127096 | Rowe et al. | May 2015 | A1 |
20150134055 | Spence et al. | May 2015 | A1 |
20150139911 | Santamore et al. | May 2015 | A1 |
20150141855 | Inoue | May 2015 | A1 |
20150142101 | Coleman et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150142105 | Bolling et al. | May 2015 | A1 |
20150150678 | Brecker | Jun 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150157459 | Macoviak et al. | Jun 2015 | A1 |
20150164637 | Khairkhahan et al. | Jun 2015 | A1 |
20150164639 | Starksen et al. | Jun 2015 | A1 |
20150164641 | Annest | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150173898 | Drasler et al. | Jun 2015 | A1 |
20150173900 | Hauser et al. | Jun 2015 | A1 |
20150190229 | Seguin | Jul 2015 | A1 |
20150196390 | Ma et al. | Jul 2015 | A1 |
20150196393 | Vidlund et al. | Jul 2015 | A1 |
20150202043 | Zakai et al. | Jul 2015 | A1 |
20150209137 | Quadri et al. | Jul 2015 | A1 |
20150209139 | Granada et al. | Jul 2015 | A1 |
20150216655 | Lane et al. | Aug 2015 | A1 |
20150216661 | Hacohen et al. | Aug 2015 | A1 |
20150223802 | Tegzes | Aug 2015 | A1 |
20150223934 | Vidlund et al. | Aug 2015 | A1 |
20150223935 | Subramanian et al. | Aug 2015 | A1 |
20150230920 | Alfieri et al. | Aug 2015 | A1 |
20150230921 | Chau et al. | Aug 2015 | A1 |
20150238312 | Lashinski | Aug 2015 | A1 |
20150238313 | Spence et al. | Aug 2015 | A1 |
20150238314 | Bortlein et al. | Aug 2015 | A1 |
20150238729 | Jenson et al. | Aug 2015 | A1 |
20150250590 | Gries et al. | Sep 2015 | A1 |
20150257877 | Hernandez | Sep 2015 | A1 |
20150257878 | Lane et al. | Sep 2015 | A1 |
20150257879 | Bortlein et al. | Sep 2015 | A1 |
20150257881 | Bortlein et al. | Sep 2015 | A1 |
20150257882 | Bortlein et al. | Sep 2015 | A1 |
20150272734 | Sheps et al. | Oct 2015 | A1 |
20150272737 | Dale et al. | Oct 2015 | A1 |
20150305861 | Annest | Oct 2015 | A1 |
20150305864 | Quadri et al. | Oct 2015 | A1 |
20150313739 | Hummen et al. | Nov 2015 | A1 |
20150320553 | Chau et al. | Nov 2015 | A1 |
20150327999 | Board et al. | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150342733 | Alkhatib et al. | Dec 2015 | A1 |
20150351906 | Hammer et al. | Dec 2015 | A1 |
20150351908 | Keranen et al. | Dec 2015 | A1 |
20150359628 | Keranen | Dec 2015 | A1 |
20150359629 | Ganesan et al. | Dec 2015 | A1 |
20150359631 | Sheahan et al. | Dec 2015 | A1 |
20150366666 | Khairkhahan et al. | Dec 2015 | A1 |
20150374495 | Ruyra Baliarda et al. | Dec 2015 | A1 |
20160000562 | Siegel | Jan 2016 | A1 |
20160000564 | Buchibnder et al. | Jan 2016 | A1 |
20160000983 | Mohl et al. | Jan 2016 | A1 |
20160008129 | Siegel | Jan 2016 | A1 |
20160015513 | Lashinski et al. | Jan 2016 | A1 |
20160015514 | Lashinski et al. | Jan 2016 | A1 |
20160015515 | Lashinski et al. | Jan 2016 | A1 |
20160030171 | Quijano et al. | Feb 2016 | A1 |
20160038246 | Wang et al. | Feb 2016 | A1 |
20160038280 | Morriss et al. | Feb 2016 | A1 |
20160038283 | Divekar et al. | Feb 2016 | A1 |
20160038286 | Yellin et al. | Feb 2016 | A1 |
20160074160 | Christianson et al. | Mar 2016 | A1 |
20160106539 | Buchbinder et al. | Apr 2016 | A1 |
20160113764 | Sheahan et al. | Apr 2016 | A1 |
20160113765 | Ganesan et al. | Apr 2016 | A1 |
20160113766 | Ganesan et al. | Apr 2016 | A1 |
20160113768 | Ganesan et al. | Apr 2016 | A1 |
20160120643 | Kupumbati | May 2016 | A1 |
20160143730 | Kheradvar | May 2016 | A1 |
20160151154 | Gorman, III et al. | Jun 2016 | A1 |
20160151156 | Seguin et al. | Jun 2016 | A1 |
20160151552 | Solem | Jun 2016 | A1 |
20160157999 | Lane et al. | Jun 2016 | A1 |
20160158000 | Granada et al. | Jun 2016 | A1 |
20160158001 | Wallace et al. | Jun 2016 | A1 |
20160158002 | Wallace et al. | Jun 2016 | A1 |
20160158003 | Wallace et al. | Jun 2016 | A1 |
20160184095 | Spence et al. | Jun 2016 | A1 |
20160206280 | Vidlund et al. | Jul 2016 | A1 |
20160206424 | Al-Jilaihawi et al. | Jul 2016 | A1 |
20160262881 | Schankereli et al. | Sep 2016 | A1 |
20160317290 | Chau et al. | Nov 2016 | A1 |
20170079790 | Vidlund et al. | Mar 2017 | A1 |
20170100248 | Tegels et al. | Apr 2017 | A1 |
20170100250 | Marsot et al. | Apr 2017 | A1 |
20170119526 | Luong et al. | May 2017 | A1 |
20170128198 | Cartledge et al. | May 2017 | A1 |
20170128205 | Tamir et al. | May 2017 | A1 |
20170128206 | Rafiee et al. | May 2017 | A1 |
20170128208 | Christianson et al. | May 2017 | A1 |
20170156860 | Lashinski | Jun 2017 | A1 |
20170165054 | Benson et al. | Jun 2017 | A1 |
20170165055 | Hauser et al. | Jun 2017 | A1 |
20170165064 | Nyuli | Jun 2017 | A1 |
20170172737 | Kuetting et al. | Jun 2017 | A1 |
20170181851 | Annest | Jun 2017 | A1 |
20170189177 | Schweich, Jr. et al. | Jul 2017 | A1 |
20170189179 | Ratz et al. | Jul 2017 | A1 |
20170189180 | Alkhatib | Jul 2017 | A1 |
20170189181 | Alkhatib et al. | Jul 2017 | A1 |
20170196688 | Christianson et al. | Jul 2017 | A1 |
20170231762 | Quadri et al. | Aug 2017 | A1 |
20170231763 | Yellin et al. | Aug 2017 | A1 |
20170258585 | Marquez et al. | Sep 2017 | A1 |
20170266001 | Vidlund et al. | Sep 2017 | A1 |
20170281345 | Yang et al. | Oct 2017 | A1 |
20170290659 | Ulmer et al. | Oct 2017 | A1 |
20170296338 | Cambell et al. | Oct 2017 | A1 |
20170296339 | Thambar et al. | Oct 2017 | A1 |
20170319333 | Tegels et al. | Nov 2017 | A1 |
20170325842 | Siegel | Nov 2017 | A1 |
20170325941 | Wallace et al. | Nov 2017 | A1 |
20170325945 | Dale et al. | Nov 2017 | A1 |
20170325948 | Wallace et al. | Nov 2017 | A1 |
20170325949 | Rodgers et al. | Nov 2017 | A1 |
20170325953 | Klima et al. | Nov 2017 | A1 |
20170325954 | Perszyk | Nov 2017 | A1 |
20170333186 | Spargias | Nov 2017 | A1 |
20170333188 | Carpentier et al. | Nov 2017 | A1 |
20170340440 | Ratz et al. | Nov 2017 | A1 |
20170348097 | Taft et al. | Dec 2017 | A1 |
20170348098 | Rowe et al. | Dec 2017 | A1 |
20170348100 | Lane et al. | Dec 2017 | A1 |
20170354496 | Quadri et al. | Dec 2017 | A1 |
20170354497 | Quadri et al. | Dec 2017 | A1 |
20170354499 | Granada et al. | Dec 2017 | A1 |
20170360426 | Hacohen et al. | Dec 2017 | A1 |
20170360549 | Lashinski et al. | Dec 2017 | A1 |
20170360558 | Ma | Dec 2017 | A1 |
20170360585 | White | Dec 2017 | A1 |
20170361065 | Legaspi et al. | Dec 2017 | A1 |
Number | Date | Country |
---|---|---|
1440261 | Sep 2003 | CN |
101076290 | Nov 2007 | CN |
101291637 | Oct 2008 | CN |
103491900 | Jan 2014 | CN |
19605042 | Jan 1998 | DE |
102006052564 | Dec 2007 | DE |
186104 | Jul 1986 | EP |
1512383 | Mar 2005 | EP |
1545371 | Jun 2005 | EP |
1551274 | Jul 2005 | EP |
1629794 | Mar 2006 | EP |
1646332 | Apr 2006 | EP |
1702247 | Sep 2006 | EP |
1734903 | Dec 2006 | EP |
1891914 | Feb 2008 | EP |
2026280 | Feb 2009 | EP |
2037829 | Mar 2009 | EP |
2081519 | Jul 2009 | EP |
2111190 | Oct 2009 | EP |
2142143 | Jan 2010 | EP |
2167742 | Mar 2010 | EP |
2278944 | Feb 2011 | EP |
2306821 | Apr 2011 | EP |
2327429 | Jun 2011 | EP |
2400924 | Jan 2012 | EP |
2400926 | Jan 2012 | EP |
2410947 | Feb 2012 | EP |
2416739 | Feb 2012 | EP |
2419050 | Feb 2012 | EP |
2444031 | Apr 2012 | EP |
2488126 | Aug 2012 | EP |
2509538 | Oct 2012 | EP |
2522307 | Nov 2012 | EP |
2549955 | Jan 2013 | EP |
2549956 | Jan 2013 | EP |
2566416 | Mar 2013 | EP |
2586492 | May 2013 | EP |
2618784 | Jul 2013 | EP |
2623068 | Aug 2013 | EP |
2626012 | Aug 2013 | EP |
2626013 | Aug 2013 | EP |
2629699 | Aug 2013 | EP |
2633457 | Sep 2013 | EP |
2637659 | Sep 2013 | EP |
2641569 | Sep 2013 | EP |
2644158 | Oct 2013 | EP |
2654624 | Oct 2013 | EP |
2656794 | Oct 2013 | EP |
2656795 | Oct 2013 | EP |
2656795 | Oct 2013 | EP |
2656796 | Oct 2013 | EP |
2656796 | Oct 2013 | EP |
2667823 | Dec 2013 | EP |
2670358 | Dec 2013 | EP |
2670358 | Dec 2013 | EP |
2676640 | Dec 2013 | EP |
2688041 | Jan 2014 | EP |
2693984 | Feb 2014 | EP |
2697721 | Feb 2014 | EP |
2713953 | Apr 2014 | EP |
2714068 | Apr 2014 | EP |
2723272 | Apr 2014 | EP |
2723273 | Apr 2014 | EP |
2723277 | Apr 2014 | EP |
2739214 | Jun 2014 | EP |
2741711 | Jun 2014 | EP |
2750630 | Jul 2014 | EP |
2750631 | Jul 2014 | EP |
2755562 | Jul 2014 | EP |
2755602 | Jul 2014 | EP |
2757962 | Jul 2014 | EP |
2777616 | Sep 2014 | EP |
2777617 | Sep 2014 | EP |
2782523 | Oct 2014 | EP |
2785282 | Oct 2014 | EP |
2786817 | Oct 2014 | EP |
2790609 | Oct 2014 | EP |
2793751 | Oct 2014 | EP |
2809263 | Dec 2014 | EP |
2810620 | Dec 2014 | EP |
2814428 | Dec 2014 | EP |
2814429 | Dec 2014 | EP |
2819617 | Jan 2015 | EP |
2819618 | Jan 2015 | EP |
2819619 | Jan 2015 | EP |
2717803 | Feb 2015 | EP |
2833836 | Feb 2015 | EP |
2838475 | Feb 2015 | EP |
2839815 | Feb 2015 | EP |
2844190 | Mar 2015 | EP |
2849680 | Mar 2015 | EP |
2849681 | Mar 2015 | EP |
2852354 | Apr 2015 | EP |
2854719 | Apr 2015 | EP |
2870933 | May 2015 | EP |
2873011 | May 2015 | EP |
2875797 | May 2015 | EP |
2760375 | Jun 2015 | EP |
2882374 | Jun 2015 | EP |
2886082 | Jun 2015 | EP |
2886083 | Jun 2015 | EP |
2886084 | Jun 2015 | EP |
2895111 | Jul 2015 | EP |
2901966 | Aug 2015 | EP |
2907479 | Aug 2015 | EP |
2911594 | Sep 2015 | EP |
2945572 | Nov 2015 | EP |
2948094 | Dec 2015 | EP |
2948102 | Dec 2015 | EP |
2964152 | Jan 2016 | EP |
2967847 | Jan 2016 | EP |
2967859 | Jan 2016 | EP |
2967860 | Jan 2016 | EP |
2967866 | Jan 2016 | EP |
2968847 | Jan 2016 | EP |
2976043 | Jan 2016 | EP |
2981208 | Feb 2016 | EP |
2982336 | Feb 2016 | EP |
2999433 | Mar 2016 | EP |
3003187 | Apr 2016 | EP |
3003219 | Apr 2016 | EP |
3003220 | Apr 2016 | EP |
3010447 | Apr 2016 | EP |
3013281 | May 2016 | EP |
3017792 | May 2016 | EP |
3021792 | May 2016 | EP |
3023117 | May 2016 | EP |
3027143 | Jun 2016 | EP |
3033048 | Jun 2016 | EP |
3037064 | Jun 2016 | EP |
3079633 | Oct 2016 | EP |
3229736 | Nov 2016 | EP |
2470119 | May 2017 | EP |
2999436 | May 2017 | EP |
3184081 | Jun 2017 | EP |
3191027 | Jul 2017 | EP |
2611389 | Aug 2017 | EP |
3082656 | Aug 2017 | EP |
3206628 | Aug 2017 | EP |
2010103 | Sep 2017 | EP |
2509538 | Sep 2017 | EP |
3223751 | Oct 2017 | EP |
3027144 | Nov 2017 | EP |
3110368 | Nov 2017 | EP |
3110369 | Nov 2017 | EP |
3132773 | Nov 2017 | EP |
3245980 | Nov 2017 | EP |
3250154 | Dec 2017 | EP |
3256074 | Dec 2017 | EP |
3256077 | Dec 2017 | EP |
3258883 | Dec 2017 | EP |
3270825 | Jan 2018 | EP |
3273910 | Jan 2018 | EP |
6504516 | May 1994 | JP |
H10258124 | Sep 1998 | JP |
2002509756 | Apr 2002 | JP |
2005280917 | Oct 2005 | JP |
2008528117 | Jul 2008 | JP |
2008541863 | Nov 2008 | JP |
2009195712 | Sep 2009 | JP |
2010518947 | Jun 2010 | JP |
5219518 | Jun 2013 | JP |
WO-1992017118 | Oct 1992 | WO |
WO-1995016407 | Jun 1995 | WO |
WO-1999004730 | Feb 1999 | WO |
WO-1999039648 | Aug 1999 | WO |
WO-1999049799 | Oct 1999 | WO |
WO-2001010343 | Feb 2001 | WO |
WO-2002003892 | Jan 2002 | WO |
WO-2002028421 | Apr 2002 | WO |
WO-2002039908 | May 2002 | WO |
WO-2003043685 | May 2003 | WO |
WO-2004084746 | Oct 2004 | WO |
WO-2004093728 | Nov 2004 | WO |
WO-2004096097 | Nov 2004 | WO |
WO-2004112657 | Dec 2004 | WO |
WO-2005002466 | Jan 2005 | WO |
WO-2005007219 | Jan 2005 | WO |
WO-2005009285 | Feb 2005 | WO |
WO-2005009506 | Feb 2005 | WO |
WO-2005087140 | Sep 2005 | WO |
WO-2006041877 | Apr 2006 | WO |
WO-2006063199 | Jun 2006 | WO |
WO-2007008371 | Jan 2007 | WO |
WO-2007067820 | Jun 2007 | WO |
2007098232 | Aug 2007 | WO |
WO-2008022077 | Feb 2008 | WO |
WO-2008028569 | Mar 2008 | WO |
WO-2008035337 | Mar 2008 | WO |
2008046593 | Apr 2008 | WO |
2008103722 | Aug 2008 | WO |
WO-2008103497 | Aug 2008 | WO |
WO-2008129405 | Oct 2008 | WO |
WO-2009045338 | Apr 2009 | WO |
2009091509 | Jul 2009 | WO |
WO-2010006627 | Jan 2010 | WO |
WO-2010008549 | Jan 2010 | WO |
WO-2010057262 | May 2010 | WO |
WO-2010080594 | Jul 2010 | WO |
WO-2010098857 | Sep 2010 | WO |
WO-2010099032 | Sep 2010 | WO |
2010121076 | Oct 2010 | WO |
WO-2010117680 | Oct 2010 | WO |
2011025981 | Mar 2011 | WO |
WO-2011047168 | Apr 2011 | WO |
WO-2011051043 | May 2011 | WO |
WO-2011057087 | May 2011 | WO |
WO-2011072084 | Jun 2011 | WO |
WO-2011106137 | Sep 2011 | WO |
WO-2011106544 | Sep 2011 | WO |
WO-2011111047 | Sep 2011 | WO |
WO-2011137531 | Nov 2011 | WO |
WO-2011139747 | Nov 2011 | WO |
WO-2012011018 | Jan 2012 | WO |
WO-2012011108 | Jan 2012 | WO |
WO-2012027487 | Mar 2012 | WO |
WO-2012035279 | Mar 2012 | WO |
WO-2012040655 | Mar 2012 | WO |
2012052718 | Apr 2012 | WO |
WO-2012047644 | Apr 2012 | WO |
WO-2012055498 | May 2012 | WO |
WO-2012087842 | Jun 2012 | WO |
WO-2012095455 | Jul 2012 | WO |
2012106602 | Aug 2012 | WO |
WO-2012102928 | Aug 2012 | WO |
WO-2012106602 | Aug 2012 | WO |
WO-2012118508 | Sep 2012 | WO |
WO-2012118816 | Sep 2012 | WO |
WO-2012118894 | Sep 2012 | WO |
WO-2012177942 | Dec 2012 | WO |
WO-2013021374 | Feb 2013 | WO |
WO-2013021375 | Feb 2013 | WO |
WO-2013028387 | Feb 2013 | WO |
WO-2013059743 | Apr 2013 | WO |
WO-2013059747 | Apr 2013 | WO |
WO-2013114214 | Aug 2013 | WO |
WO-2013120181 | Aug 2013 | WO |
WO-2013123059 | Aug 2013 | WO |
WO-2013128432 | Sep 2013 | WO |
WO-2013130641 | Sep 2013 | WO |
WO-2013131925 | Sep 2013 | WO |
WO-2013140318 | Sep 2013 | WO |
WO-2013148017 | Oct 2013 | WO |
WO-2013148018 | Oct 2013 | WO |
WO-2013148019 | Oct 2013 | WO |
WO-2013150512 | Oct 2013 | WO |
WO-2013152161 | Oct 2013 | WO |
WO-2013158613 | Oct 2013 | WO |
WO-2013169448 | Nov 2013 | WO |
WO-2013175468 | Nov 2013 | WO |
WO-2013176583 | Nov 2013 | WO |
WO-2013188077 | Dec 2013 | WO |
WO-2013192107 | Dec 2013 | WO |
WO-2014036113 | Mar 2014 | WO |
WO-2014043527 | Mar 2014 | WO |
WO-2014047111 | Mar 2014 | WO |
WO-2014047325 | Mar 2014 | WO |
WO-2014055981 | Apr 2014 | WO |
WO-2014059432 | Apr 2014 | WO |
WO-2014064694 | May 2014 | WO |
WO-2014066365 | May 2014 | WO |
WO-2014089424 | Jun 2014 | WO |
WO-2014093861 | Jun 2014 | WO |
WO-2014111918 | Jul 2014 | WO |
WO-2014114794 | Jul 2014 | WO |
WO-2014114795 | Jul 2014 | WO |
WO-2014114796 | Jul 2014 | WO |
WO-2014114798 | Jul 2014 | WO |
WO-2014116502 | Jul 2014 | WO |
WO-2014121280 | Aug 2014 | WO |
WO-2014128705 | Aug 2014 | WO |
WO-2014134277 | Sep 2014 | WO |
WO-2014138194 | Sep 2014 | WO |
WO-2014138284 | Sep 2014 | WO |
WO-2014138482 | Sep 2014 | WO |
WO-2014138868 | Sep 2014 | WO |
WO-2014144100 | Sep 2014 | WO |
WO-2014144937 | Sep 2014 | WO |
WO-2014145338 | Sep 2014 | WO |
WO-2014147336 | Sep 2014 | WO |
WO-2014152306 | Sep 2014 | WO |
WO-2014152375 | Sep 2014 | WO |
WO-2014152503 | Sep 2014 | WO |
WO-2014153544 | Sep 2014 | WO |
WO-2014158617 | Oct 2014 | WO |
WO-2014162181 | Oct 2014 | WO |
WO-2014162306 | Oct 2014 | WO |
WO-2014163705 | Oct 2014 | WO |
WO-2014168655 | Oct 2014 | WO |
WO-2014179391 | Nov 2014 | WO |
WO-2014181336 | Nov 2014 | WO |
WO-2014189974 | Nov 2014 | WO |
2014200764 | Dec 2014 | WO |
WO-2014191994 | Dec 2014 | WO |
WO-2014194178 | Dec 2014 | WO |
WO-2014201384 | Dec 2014 | WO |
WO-2014201452 | Dec 2014 | WO |
WO-2014205064 | Dec 2014 | WO |
WO-2014207699 | Dec 2014 | WO |
WO-2014210124 | Dec 2014 | WO |
WO-2014210299 | Dec 2014 | WO |
WO-2015009503 | Jan 2015 | WO |
WO-2015020971 | Feb 2015 | WO |
2015031898 | Mar 2015 | WO |
WO-2015028986 | Mar 2015 | WO |
2015061558 | Apr 2015 | WO |
WO-2015051430 | Apr 2015 | WO |
WO-2015052663 | Apr 2015 | WO |
WO-2015057407 | Apr 2015 | WO |
WO-2015057735 | Apr 2015 | WO |
WO-2015057995 | Apr 2015 | WO |
WO-2015061378 | Apr 2015 | WO |
WO-2015061431 | Apr 2015 | WO |
WO-2015061463 | Apr 2015 | WO |
WO-2015061533 | Apr 2015 | WO |
WO-2015075128 | May 2015 | WO |
WO-2015081775 | Jun 2015 | WO |
WO-2015089334 | Jun 2015 | WO |
WO-2015092554 | Jun 2015 | WO |
WO-2015120122 | Aug 2015 | WO |
WO-2015125024 | Aug 2015 | WO |
WO-2015127264 | Aug 2015 | WO |
WO-2015127283 | Aug 2015 | WO |
WO-2015128739 | Sep 2015 | WO |
WO-2015128741 | Sep 2015 | WO |
WO-2015128747 | Sep 2015 | WO |
WO-2015132667 | Sep 2015 | WO |
WO-2015132668 | Sep 2015 | WO |
WO-2015135050 | Sep 2015 | WO |
WO-2015142648 | Sep 2015 | WO |
WO-2015142834 | Sep 2015 | WO |
WO-2015148241 | Oct 2015 | WO |
2015179181 | Nov 2015 | WO |
WO-2015171190 | Nov 2015 | WO |
WO-2015171743 | Nov 2015 | WO |
WO-2015191604 | Dec 2015 | WO |
WO-2015191839 | Dec 2015 | WO |
WO-2015195823 | Dec 2015 | WO |
2016005803 | Jan 2016 | WO |
WO-2016011185 | Jan 2016 | WO |
WO-2016020918 | Feb 2016 | WO |
WO-2016027272 | Feb 2016 | WO |
WO-2016059533 | Apr 2016 | WO |
WO-2016065158 | Apr 2016 | WO |
WO-2016073741 | May 2016 | WO |
WO-2016083551 | Jun 2016 | WO |
WO-2016093877 | Jun 2016 | WO |
WO-2016097337 | Jun 2016 | WO |
WO-2016108181 | Jul 2016 | WO |
2016133950 | Aug 2016 | WO |
WO-2017062640 | Apr 2017 | WO |
2017087701 | May 2017 | WO |
2017096157 | Jun 2017 | WO |
2017100927 | Jun 2017 | WO |
2017101232 | Jun 2017 | WO |
2017117388 | Jul 2017 | WO |
2017127939 | Aug 2017 | WO |
2017136287 | Aug 2017 | WO |
2017136596 | Aug 2017 | WO |
2017165810 | Sep 2017 | WO |
2017192960 | Nov 2017 | WO |
2017196511 | Nov 2017 | WO |
2017196909 | Nov 2017 | WO |
2017196977 | Nov 2017 | WO |
2017197064 | Nov 2017 | WO |
2017197065 | Nov 2017 | WO |
2017189040 | Dec 2017 | WO |
2017218671 | Dec 2017 | WO |
2018017886 | Jan 2018 | WO |
Entry |
---|
US 9,265,606 B2, 02/2016, Buchbinder et al. (withdrawn) |
International Search Report and Written Opinion dated Jul. 11, 2018 for PCT Application No. PCT/US2018/027990, 15 pages. |
International Search Report and Written Opinion dated Jun. 28, 2018 for PCT Application No. PCT/US2018/027983, 15 pages. |
International Search Report and Written Opinion dated Aug. 3, 2018 for PCT Application No. PCT/US2018035086, 15 pages. |
International Search Report and Written Opinion dated Aug. 9, 2018 for PCT Application No. PCT/US2018/035081, 11 pages. |
Bernard et al., “Aortic Valve Area Evolution After Percutaneous Aortic Valvuloplasty,” European Heart Journal, Jul. 1990, vol. 11 (2), pp. 98-107. |
BlueCross BlueShield of Northern Carolina Corporate Medical Policy “Balloon valvuloplasty, Percutaneous”, (Jun. 1994). |
Cimino et al., “Physics of Ultrasonic Surgery Using Tissue Fragmentation: Part I and Part II”, Ultrasound in Medicine and Biologyl, Jun. 1996, vol. 22 (1), pp. 89-100, and pp. 101-117. |
Cimino, “Ultrasonic Surgery: Power Quantification and Efficiency Optimization”, Aesthetic Surgery Journal, Feb. 2001, pp. 233-241. |
Cowell et al., “A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis,” NEJM, Jun. 2005, vol. 352 (23), pp. 2389-2397. |
De Korte et al., “Characterization of Plaque Components and Vulnerability with Intravascular Ultrasound Elastography”, Phys. Med. Biol., Feb. 2000, vol. 45, pp. 1465-1475. |
European Search Report dated Mar. 13, 2015 for European Application. No. 05853460.3. |
Feldman, “Restenosis Following Successful Balloon Valvuloplasty: Bone Formation in Aortic Valve Leaflets”, Cathet Cardiovasc Diagn, May 1993, vol. 29 (1), pp. 1-7. |
Fitzgerald et al., “Intravascular Sonotherapy Decreased Neointimal Hyperplasia After Stent Implantation in Swine”, Circulation, Feb. 2001, vol. 103, pp. 1828-1831. |
Freeman et al., “Ultrasonic Aortic Valve Decalcification: Serial Doppler Echocardiographic Follow Up”, J Am Coll Cardiol., Sep. 1990, vol. 16 (3), pp. 623-630. |
Greenleaf et al., “Selected Methods for Imaging Elastic Properties of Biological Tissues”, Annu. Rev. Biomed. Eng., Apr. 2003, vol. 5, pp. 57-78. |
Gunn et al., “New Developments in Therapeutic Ultrasound-Assisted Coronary Angioplasty”, Curr Interv Cardiol Rep., Dec. 1990, vol. 1 (4), pp. 281-290. |
Guzman et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius”, Ultrasound in Med. & Biol., Mar. 2003, vol. 29 (8), pp. 1211-1222. |
Hallgrimsson et al., “Chronic Non-Rheumatic Aortic Valvular Disease: a Population Study Based on Autopsies”, J Chronic Dis., Jun. 1979, vol. 32 (5), pp. 355-363. |
Isner et al., “Contrasting Histoarchitecture of Calcified Leaflets from Stenotic Bicuspid Versus Stenotic Tricuspid Aortic Valves”, J Am Coll Cardiol., Apr. 1990, vol. 15 (5), p. 1104-1108. |
Lung et al., “A Prospective Survey of Patients with Valvular Heart Disease in Europe: The Euro Heart Survey on Valvular Heart Disease”, Euro Heart Journal, Mar. 2003, vol. 24, pp. 1231-1243. |
McBride et al “Aortic Valve Decalcification”, J Thorac Cardiovas-Surg, Jul. 1990, vol. 100, pp. 36-42. |
Miller et al., “Lysis and Sonoporation of Epidermoid and Phagocytic Monolayer Cells by Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies”, Ultrasound in Med. & Biol., May 2007, vol. 27 (8), pp. 1107-1113. |
Mohler, “Mechanisms of Aortic Valve Calcificaion”, Am J Cardiol, Dec. 2004, vol. 94 (11), pp. 1396-1402. |
Otto et al., “Three-Year Outcome After Balloon Aortic Valvuloplasty. Insights into Prognosis of Valvular Aortic Stenosis”, Circulation, Feb. 1994, vol. 89, pp. 642-650. |
Passik et al., “Temporal Changes in the Causes of Aortic Stenosis: A Surgical Pathologic Study of 646 Cases”, Mayo Clin Proc, Feb. 1987, vol. 62, pp. 19-123. |
Quaden et al., “Percutaneous Aortic Valve Replacement: Resection Before Implantation”, Eur J Cardiothorac Surg, Jan. 2005, vol. 27, pp. 836-840. |
Riebman et al., “New Concepts in the Management of Patients with Aortic Valve Disease”, Abstract, Valvular Heart Disease, JACC, Mar. 2004, p. 34A. |
Rosenschein et al., “Percutaneous Transluminal Therapy of Occluded Saphenous Vein Grafts” Circulation, Jan. 1999, vol. 99, pp. 26-29. |
Sakata et al., “Percutaneous Balloon Aortic Valvuloplasty: Antegrade Transseptal vs. Conventional Retrograde Transarterial Approach”, Catheter Cardiovasc Interv., Mar. 2005, vol. 64 (3), pp. 314-321. |
Sasaki et al., “Scanning Electron Microscopy and Fourier Transformed Infrared Spectroscopy Analysis of Bone Removal Using Er:YAG and CO2 Lasers”, J Periodontol., Jun. 2002, vol. 73 (6), pp. 643-652. |
Search Report and Written Opinion dated Dec. 10, 2012 for PCT Application No. PCT/US2012/043636. |
Search Report and Written Opinion dated Dec. 6, 2016 for PCT Application No. PCT/US2016/047831. |
Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061215. |
Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061219. |
Search Report and Written Opinion dated Mar. 2, 2015 for PCT Application No. PCT/US2014/029549. |
Search Report and Written Opinion dated May 1, 2012 for PCT Application No. PCT/US2011/065627. |
Search Report and Written Opinion dated May 22, 2007 for PCT Application No. PCT/US2005/044543. |
Search Report and Written Opinion dated Oct. 20, 2014 for PCT Application No. PCT/US2014/038849. |
Search Report and Written Opinion dated Sep. 4, 2014 for PCT Application No. PCT/US2014/014704. |
The CoreValve System Medtronic, 2012, 4 Pages. |
Van Den Brand et al., “Histological Changes in the Aortic Valve after Balloon Dilation: Evidence for a Delayed Healing Process”, Br Heart J, Jun. 1992,vol. 67, pp. 445-459. |
Verdaadadonk et al., “The Mechanism of Action of the Ultrasonic Tissue Resectors Disclosed Using High-Speed and Thermal Imaging Techniques”, SPIE, Jan. 1999, vol. 3594, pp. 221-231. |
Voelker et al., “Inoperative Valvuloplasty in Calcific Aortic Stenosis: a Study Comparing the Mechanism of a Novel Expandable Device with Conventional Balloon Dilation”, Am Heart J., Nov. 1991, vol. 122 (5), pp. 1327-1333. |
Waller et al., “Catheter Balloon Valvuloplasty of Stenotic Aortic Valves. Part II: Balloon Valvuloplasty During Life Subsequent Tissue Examination”, Clin Cardiol., Nov. 1991, vol. 14 (11), pp. 924-930. |
Wang, “Balloon Aortic Valvuloplasty”, Prog Cardiovasc Dis., Jul.-Aug. 1997, vol. 40 (1), pp. 27-36. |
Wilson et al., “Elastography—The movement Begins”, Phys. Med. Biol., Jun. 2000, vol. 45, pp. 1409-1421. |
Yock et al, “Catheter-Based Ultrasound Thrombolysis”, Circulation, Mar. 1997, vol. 95 (6), pp. 1411-1416. |
U.S. Appl. No. 16/288,679, filed Feb. 28, 2019, naming inventor Deem et al. |
Number | Date | Country | |
---|---|---|---|
20180344454 A1 | Dec 2018 | US |